Medifast Lowers FY2026 GAAP EPS Guidance from $(1.75)-$(0.25) to $(2.05)-$(1.80) vs $(0.94) Est
Benzinga Newsdesk 3 weeks ago
NewsGuidance
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Medifast (NYSE:MED) lowers FY2026 GAAP EPS guidance from $(1.75)-$(0.25) to $(2.05)-$(1.80) vs $(0.94) analyst estimate..
Medifast (NYSE:MED) lowers FY2026 GAAP EPS guidance from $(1.75)-$(0.25) to $(2.05)-$(1.80) vs $(0.94) analyst estimate..
